Importantly, since SGLT2 inhibitors achieve their glucose-lowering effect through an insulin-independent mechanism, they permit lower insulin requirements of subjects with T2DM and can be used effectively in any stage of T2DM (Vallon, 2015). This evidence concerns the gene INS and type 2 diabetes mellitus.